CGF Pharmatech inc.

CGF Pharmatech inc.

Founded in 1990, CGF Pharmatech Inc. first developed its capacities to distribute and market third-party pharmaceutical and biological products, mostly in the areas of organ transplantation and vaccines. The expertise developed by the company includes mass distribution of temperature-sensitive products (more than 5 million doses
of vaccines distributed in 1992 and 1993 on behalf of the
Ministre de la Sant du Qubec), as well as controlled
distribution of specialty products (clinical trial materials,
drugs distributed under the Emergency Drug Regulations).
The company has developed a significant niche market for
vaccines (private medical clinics and pharmacies), and for
immuno-suppressive globulins used for organ transplantation.

Since 1992, CGF Pharmatech Inc. develops and markets
dedicated software applications for the management of
inventories and controlled distribution of Clinical Trial
materials, for the management of vaccines inventories in
public health units, and for the management of commercial
activities of small to medium sized biotech and pharma
companies.

FACILITIES:
3000 cubic feet of refrigerated space (2-8C).
100 cubic feet of deep-freeze space (below -20C).
1500 sq. ft. storage facility.
The refrigerated and deep-freeze equipment are fully equipped with
electronic monitoring and alarm devices, as well as emergency
power back-up.

BUSINESS STRATEGY:
Expansion of the product line through distribution
agreements (exclusive and non-exclusive), including
products for research and clinical laboratories.
Market expansion for the software applications, with an
emphasis on the products for the control of Clinical Trial
Materials distribution on the North-American and European
markets. Development of the in-house R&D program
(described below).

RESEARCH & DEVELOPMENT:
In 1992, CGF Pharmatech Inc. initiated the development of
a software application for advanced determination of
immunological properties of protein domains. This R&D program,
based on previous successes in the area of HIV immunology, is
most particularly aimed at identification of sequences
responsible for major side-effects in some human vaccines.

Company Details

Year Established: 1990

Company Information

Jean-paul Chausseau
Title: President
Telephone: (514) 343-0344
Fax: (514) 343-0340

Products

Vaccines

Immuno-suppressive Globulins

Services

Software Applications Software applications for public health units, for medical departments of pharmaceutical companies, and for biotech companies.

Biotechnology